Gene Therapy for Alzheimer's Disease

$1,558,722P01FY2011AGNIH

University Of California, San Diego, La Jolla CA

Investigators

Linked publications & trials

Paper 29535375 Paper 29045838 Paper 28130011 Paper 28067668 Paper 27558862 Paper 27525439 Paper 27466341 Paper 27419933 Paper 26948893 Paper 26903653 Paper 26620558 Paper 26489892 Paper 26388203 Paper 26341908 Paper 26302439 Paper 26202279 Paper 25803611 Paper 25788688 Paper 25673831 Paper 25533483 Paper 25505106 Paper 25448159 Paper 25173807 Paper 25126588 Paper 25093680 Paper 25024337 Paper 25022790 Paper 24885390 Paper 24825898 Paper 24813892 Paper 24462903 Paper 24068826 Paper 23935974 Paper 23626796 Paper 23413261 Paper 23401561 Paper 23392688 Paper 23384597 Paper 23313024 Paper 23254192 Paper 23223568 Paper 23182244 Paper 23152192 Paper 22989354 Paper 22833673 Paper 22810100 Paper 22647715 Paper 22528101 Paper 22514658 Paper 22508489 Paper 22492998 Paper 22456708 Paper 22314685 Paper 22281106 Paper 22229116 Paper 22211740 Paper 22150925 Paper 22112803 Paper 22066148 Paper 22064070 Paper 21998872 Paper 21994367 Paper 21928509 Paper 21860085 Paper 21403389 Paper 21368891 Paper 21358740 Paper 21304989 Paper 21296890 Paper 21257908 Paper 21103359 Paper 21045796 Paper 20970422 Paper 20679195 Paper 20559548 Paper 20554871 Paper 20445049 Paper 20433905 Paper 20413653 Paper 20181623 Paper 20140000 Paper 20091183 Paper 19944097 Paper 19932737 Paper 19931251 Paper 19864570 Paper 19726646 Paper 19660551 Paper 19651612 Paper 19587288 Paper 19551456 Paper 19535597 Paper 19416837 Paper 19321231 Paper 19198615 Paper 19176820 Paper 19166511 Paper 19135265 Paper 19014502 Paper 19013154

Abstract

The aim of this Program Project is to explore influences of genes and the environment on neuronal vulnerability to degeneration in aging and Alzheimer's disease (AD), thereby identifying potential translational therapies for humans with AD. The resubmission of this program project will both build upon progress from the previous period of funding, and explore new evidence that physical activity influences cognitive and cellular features of neural function. Each project focuses on these central themes while examining individual mechanisms and specific models in detail. Project 1 focuses on effects of Neuregulin 1 gene expression on AB load, neuronal structure, neurogenesis and behavior on a background of aging and amyloid mutations in mice. Project 2 tests the hypothesis that genetic approaches to modifying amyloid processing, including overexpression of amyloid-degrading enzymes, can improve neuronal structural, electrophysiology, neurogenesis and behavior in amyloid mutant mice. Project 3 examines the extent to which glutamatergic and nicotinic mechanisms influence amyloid processing, caspace activation, neural structure and neurogenesis. Project 4 tests the hypothesis that BDNF ameliorates neuronal dysfunction and death in primate models of entorhinal/hippocampal degeneration using methods clinically practical in AD, and explores whether augmented physical activity in aged primates improves neuronal structure, cognitive ability and neurogenesis. Core A will coordinate activities and administration of all projects and Cores, and provide statistical support. Core B, the Vector Core, will support the a variety of recombinant vector needs that constitute a common theme in all projects. Core C will provide anatomical and electrophysiological support in evaluating effects of interventions from all projects on neuronal structure, synaptic plasticity, neurogenesis and behavior. The interdependency of resources and skills between Projects/Cores, as well as our past success with this PPG, support the argument that the Program Project is the most efficient and cost-effective way to address these issues.

View original record on NIH RePORTER →